Back to top

Is Supernus Pharmaceuticals Inc (SUPN) Overvalued After Q2 Earnings Beat? EPS: -$1. ...

Is Supernus Pharmaceuticals Inc (SUPN) Overvalued After Q2 Earnings Beat? EPS: -$1.01, Revenue: $219.1M, GF Score: 87/100

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Supernus Pharmaceuticals, Inc. (SUPN)